Replacement of native adenovirus receptor-binding sites with a new attachment moiety diminishes hepatic tropism and enhances bioavailability in mice.
The in vivo efficacy of adenoviral vectors (AdVs) in gene delivery strategies is hampered by the broad tissue tropism of the virus and its efficient binding to human erythrocytes. To circumvent these limitations, we developed a prototype AdV lacking native binding sites. We replaced the adenoviral fiber with a chimeric molecule consisting of the fiber tail domain, the reovirus sigma1 oligomerization domain, and a polyhistidine tag as model targeting moiety. We also abolished the integrin-binding motif in the penton base protein. The chimeric attachment molecule was efficiently incorporated onto AdV capsids, allowed efficient propagation of AdV without requirement for complementing fiber and conferred highly specific tropism to the AdV. Importantly, the targeted AdV exhibited markedly reduced tropism for liver cells. In comparison with control AdV with native tropism, the targeted AdV showed 1000-fold reduced transduction of HepG2 cells and 10,000-fold reduced transduction of mouse liver cells in freshly isolated liver slices. After intravenous inoculation of C57BL/6 mice, the targeted AdV exhibited delayed clearance in comparison with the native AdV, leaving approximately 10-fold greater levels in the blood 2 hr after inoculation. For all tissues analyzed, the targeted AdV displayed significantly reduced in vivo transduction in comparison with the native vector. Furthermore, in contrast to the native AdV, the targeted AdV did not bind human erythrocytes. Together, our findings suggest that the targeted AdV design described here provides a promising platform for systemic in vivo gene delivery.
Schagen
Frederik H E
FH
Department of Medical Oncology, VU University Medical Center, 1181 HV Amsterdam, The Netherlands.
Graat
Harm C A
HC
Carette
Jan E
JE
Vellinga
Jort
J
van Geer
Michael A
MA
Hoeben
Rob C
RC
Dermody
Terence S
TS
van Beusechem
Victor W
VW
D000260:Adenoviruses, Human / Q000235:genetics*; D000818:Animals; D000956:Antigens, Viral / Q000235:genetics; D001665:Binding Sites; D001682:Biological Availability; D036022:Capsid Proteins / Q000235:genetics; D045744:Cell Line, Tumor; D004912:Erythrocytes / Q000821:virology; D005260:Female; D018390:Gene Targeting; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D022781:Hepatocytes / Q000821:virology*; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D051381:Rats; D014161:Transduction, Genetic; D017376:Viral Tail Proteins / Q000235:genetics
D000956:Antigens, Viral; D036022:Capsid Proteins; D017376:Viral Tail Proteins; C018315:hexon capsid protein, Adenovirus